Tempus Ai (TEM) traded down -0.67 % during a 24 hours period ending at 10:06 PM Central Europe on Tuesday 27th. One Tempus Ai stock can currently be bought for about USD 72.15 on popular exchanges. Current supply of Tempus Ai stocks is 187.3 mn. Tempus Ai has a current market capitalization of USD 12.2 bn and approximately USD 253.1 mn worth of Tempus Ai was traded on exchanges in the last 24 hours. Since last month end, Tempus Ai has traded -21.06 % down. Simple moving average of last 200 days is at USD 56.8. The highest price of past 52 weeks was recorded at USD 91.83 on 10/30/2025. 52 weeks low was at USD 40.77 on 07/28/2026.
Summary of the latest news for Tempus Ai
Tempus AI Inc. announced that its xR RNA sequencing assay has obtained certification under the European Union’s In Vitro Diagnostic Regulation as a Class C device. The certification confirms compliance of the company’s quality management system for next‑generation sequencing tools used in cancer genomic profiling. The xR assay, which detects gene rearrangements and splice variants in solid tumors, has been shown to enhance detection of clinically actionable gene fusions when combined with DNA testing. The certification will allow continued access to the product in the EU beyond the 2028 transition deadline for legacy devices and provides a regulated platform for biopharmaceutical partners supporting clinical studies. The company highlighted that the approval reinforces its commitment to high regulatory standards and supports expansion of its RNA sequencing capabilities across European healthcare providers, partners, and patients.
Here is how related stocks have performed in the past 24 hours:
Assurant (AIZ) traded up 0.84 % and now trades at USD 286.3. Assurant has a market capitalisation of USD 14.1 bn. Assurant has a current price to earnings ratio of 13.63.
Gartner (IT) traded up 0.33 % and now trades at USD 220.93. Gartner has a market capitalisation of USD 14.6 bn. Gartner has a current price to earnings ratio of 21.23.
Neurocrine Biosciences (NBIX) traded up 2.22 % and now trades at USD 146. Current market capitalisation for Neurocrine Biosciences is USD 14.6 bn. Current price/earnings ratio for Neurocrine Biosciences is 20.83.
Halozyme Therapeutics (HALO) traded up 1.89 % and now trades at USD 128.5. Halozyme Therapeutics has a market capitalisation of USD 14.4 bn. Current price/earnings ratio for Halozyme Therapeutics is 37.28.
Solventum (SOLV) traded up 0.47 % and now trades at USD 82.98. Solventum has a market capitalisation of USD 14.5 bn. Current price/earnings ratio for Solventum is 9.3. SOLVENTUM CORP has entered into a series of agreements with 3M India Limited to expand its presence in the health‑care sector. The contracts include a distribution arrangement, a licensed manufacturer and reseller agreement, and a sales‑agent partnership, all effective from March 2024. Subsequent amendments modify the scope of these agreements, removing certain products that have been divested to Thermo Fisher and extending the term for the remaining products by an additional two years. The divestiture triggers a one‑time compensation payment and establishes a framework for future product transitions, with compensation tied to prior sales performance. These developments signal a strategic realignment of SOLVENTUM’s product portfolio and its partnership structure within the industry.